Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H30N4O4 |
Molecular Weight | 402.4873 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C(C=C(C(N)=C1)[N+]([O-])=O)C(=O)NC2CCN(CC3CCC=CC3)CC2
InChI
InChIKey=ZDLBNXXKDMLZMF-UHFFFAOYSA-N
InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)
Molecular Formula | C21H30N4O4 |
Molecular Weight | 402.4873 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Cinitapride is an agonist of 5-HT4 and 5-HT1 receptors and antagonist of 5-HT2 receptors. Cinitapride is marketed worldwide for the treatment of gastrointestinal disorders related to motility such as indigestion or functional or non-ulcer dyspepsia, gastroesophageal reflux diseases, delay in gastric emptying and vomiting.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:04:23 GMT 2023
by
admin
on
Sat Dec 16 18:04:23 GMT 2023
|
Record UNII |
R8I97I2L24
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A03FA08
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
||
|
NCI_THESAURUS |
C47794
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
66564-14-5
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
SUB06298MIG
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104523
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
68867
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
100000081046
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
652
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
R8I97I2L24
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
4555
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
C77257
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
m3565
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
CINITAPRIDE
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
C045316
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
21125
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID60867232
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY | |||
|
DB08810
Created by
admin on Sat Dec 16 18:04:24 GMT 2023 , Edited by admin on Sat Dec 16 18:04:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |